Compare Axon Enterprise Inc (AXON) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs Illumina, Inc. — how do they compare? Axon Enterprise Inc trades at $601.93 (market cap $51.69B), while Illumina, Inc. trades at $190.96 (market cap $29.12B). The key difference: Axon Enterprise Inc is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.
| AXON | ILMN | |
|---|---|---|
Market Cap | $51.69B | $29.12B |
Sector | Technology | Health |
52-Week High | $791.62 | $205.10 |
52-Week Low | $345.94 | $91.00 |
Enterprise Value | $52.83B | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $616.97, up 3.46% in the last 24 hours, showing strong momentum with a bullish technical signal and consistent earnings beats. The stock is near its pivot point of $629, with support at $616 and resistance at $649. Revenue grew 35% year-over-year in Q2 2026, driven by AI and counter-drone offerings, though high valuation multiples like a P/E of 265.13 and P/S of 16.35 reflect premium pricing. Analyst consensus is strongly bullish with an $685 price target, but gross margin compression and elevated multiples pose risks.
Outlook remains positive given robust growth and AI adoption, but investors face valuation risks and margin pressures. The stock offers upside to consensus targets if execution continues, yet any growth slowdown could trigger significant multiple contraction. Key catalysts include Q3 2026 earnings and AI-driven contract expansions.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
